These proteins are potential biomarkers that could be used to predict the best treatment for each patient
They analyzed the differences in protein modulation between patients responding to celecoxib or to the combination of chondroitin sulfate and hydrochlorure of glucosamine, and patients not responding to these treatments.
The results of this study have been presented at the Osteoarthritis World Congress (OARSI) and have been accepted as scientific communication accepted for presentation at the European Congress of Rheumatology (EULAR).
This is the main conclusion of a new clinical essay that proved, by means of Quantitative Magnetic Resonance, that pharmaceutical grade chondroitin sulfate is superior to an anti-inflammatory drug (celecoxib) for delaying the disease’s progression
The results also revealed that chondroitin sulfate possesses the same level of efficiency as celecoxib for the improvement of pain and mobility in knee osteoarthritis, with the added advantage of a higher safety profile
This research project has been selected by the American Academy of Rheumatology as one of the keynote addresses of this year’s annual meeting
The article shows that there are chondroitin molecules of low efficacy and that some even produce undesired effects, such as pro-inflammatory action of the joint
According to the investigators, the huge variability in the quality and origin of raw material, as well as in extraction and purification techniques, leads to molecules with different physical and chemical properties that may jeopardise the efficacy and safety of the end products
CS b-Bioactive®, Bioiberica’s brand of chondroitin sulfate, guarantees a robust molecule, a consistent and traceable manufacturing process, and demonstrated efficacy and safety in more than 20 studies and 14 million patients treated
The results of the clinical trial MOVES have been published showing that the combination of these two active ingredients reduces pain, functional disability, joint stiffness, swelling and effusion in knee osteoarthritis
* This website is not intended to report adverse events related to Bioiberica's products. If you would like to report a suspected adverse reaction, please contact the Department of Pharmacovigilance Bioiberica.